

the duration of treatment.  
Kidney Int. 1996 50:627-34.

[0068] 20. Laight D W, et al. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev. 15: 274-82 (1999).

[0069] 21. Stehouwer C D, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 34:55-68 (1997).

[0070] 22. Horii Y, et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl. 1993 39:S71-5.

[0071] 23. Huber S A, et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999 19:2364-7.

[0072] 24. Kado S, et al. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 1999 36:67-72.

[0073] 25. Eitner F, et al. Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int. 1997 51:69-78.

[0074] 26. Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, Tomino Y. Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy. J Clin Lab Anal. 1998 12:1-5.

#### CLAIMS:

What is claimed is:

1. A method for detecting compounds that effect inflammation, comprising, a) adding to cells a composition comprising a compound suspected of effecting